RCUS
Arcus Biosciences Inc.
NYSE:RCUS
$2.5B MC · 106.4M shares · 601 employees

Arcus Biosciences Inc. Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Content on this page require a membership to view — $9/mo.

News

This data requires membership
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
biotech.bet © 2026